| Primary |
| Convulsion |
75.8% |
| Convulsion Prophylaxis |
9.1% |
| Grand Mal Convulsion |
6.1% |
| Status Epilepticus |
6.1% |
| Drug Level Decreased |
3.0% |
|
| Hypotension |
21.4% |
| Medication Error |
7.1% |
| Oxygen Saturation Decreased |
7.1% |
| Pulse Absent |
7.1% |
| Anticonvulsant Drug Level Increased |
3.6% |
| Aspartate Aminotransferase Increased |
3.6% |
| Cardiac Arrest |
3.6% |
| Delirium |
3.6% |
| Dizziness |
3.6% |
| Electromechanical Dissociation |
3.6% |
| Heart Rate Irregular |
3.6% |
| Hepatitis |
3.6% |
| Mental Status Changes |
3.6% |
| Nodal Rhythm |
3.6% |
| Pancytopenia |
3.6% |
| Paraesthesia |
3.6% |
| Product Contamination Physical |
3.6% |
| Product Outer Packaging Issue |
3.6% |
| Pyrexia |
3.6% |
| Rash Maculo-papular |
3.6% |
|
| Secondary |
| Convulsion |
37.2% |
| Product Used For Unknown Indication |
15.0% |
| Status Epilepticus |
12.3% |
| Drug Use For Unknown Indication |
7.1% |
| Grand Mal Convulsion |
5.9% |
| Foetal Exposure During Pregnancy |
3.6% |
| Hypertension |
3.6% |
| Sedation |
2.8% |
| Blood Pressure Abnormal |
1.6% |
| Metabolic Acidosis |
1.6% |
| Induction Of Anaesthesia |
1.2% |
| Partial Seizures |
1.2% |
| Pharyngitis Streptococcal |
1.2% |
| Swelling |
1.2% |
| Convulsion Prophylaxis |
0.8% |
| Epilepsy |
0.8% |
| Escherichia Bacteraemia |
0.8% |
| Haemodynamic Instability |
0.8% |
| Hypotension |
0.8% |
| Intubation |
0.8% |
|
| Toxic Epidermal Necrolysis |
20.0% |
| Death |
10.0% |
| Stevens-johnson Syndrome |
10.0% |
| Toxicity To Various Agents |
10.0% |
| Pancreatitis Acute |
7.5% |
| Metabolic Acidosis |
5.0% |
| Status Epilepticus |
5.0% |
| Bundle Branch Block Left |
2.5% |
| Convulsion |
2.5% |
| Cyst |
2.5% |
| Drug Level Below Therapeutic |
2.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.5% |
| Finger Amputation |
2.5% |
| Hepatitis |
2.5% |
| Hyponatraemia |
2.5% |
| Leukocytosis |
2.5% |
| Medication Error |
2.5% |
| Myoclonus |
2.5% |
| Pancreatic Enzymes Increased |
2.5% |
| Pancytopenia |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.1% |
| Convulsion |
18.1% |
| Drug Use For Unknown Indication |
15.9% |
| Status Epilepticus |
12.4% |
| Immunosuppression |
3.2% |
| Chemotherapy |
3.0% |
| Prophylaxis |
2.4% |
| Supplementation Therapy |
2.4% |
| Hypertension |
2.2% |
| Mucosal Inflammation |
2.0% |
| Convulsion Prophylaxis |
1.8% |
| Immune System Disorder |
1.4% |
| Premedication |
1.4% |
| Diabetes Mellitus |
1.2% |
| Nausea |
1.2% |
| Overdose |
1.2% |
| Pain |
1.2% |
| Acute Lymphocytic Leukaemia |
1.0% |
| Anaesthesia |
1.0% |
| Antiemetic Supportive Care |
1.0% |
|
| Stevens-johnson Syndrome |
19.1% |
| Convulsion |
7.4% |
| Swollen Tongue |
7.4% |
| Inborn Error Of Metabolism |
5.9% |
| Toxicity To Various Agents |
5.9% |
| Unresponsive To Stimuli |
5.9% |
| Astrocytoma |
4.4% |
| Pulmonary Embolism |
4.4% |
| Reversible Posterior Leukoencephalopathy Syndrome |
4.4% |
| Syncope |
4.4% |
| Tachycardia |
4.4% |
| Drug Ineffective |
2.9% |
| Lung Neoplasm Malignant |
2.9% |
| Metabolic Acidosis |
2.9% |
| No Therapeutic Response |
2.9% |
| Red Blood Cell Count Decreased |
2.9% |
| Renal Failure Acute |
2.9% |
| Renal Injury |
2.9% |
| Sepsis |
2.9% |
| Septic Shock |
2.9% |
|
| Interacting |
| Evidence Based Treatment |
37.5% |
| Convulsion Prophylaxis |
25.0% |
| Status Epilepticus |
25.0% |
| Hypertension |
12.5% |
|
| Electrocardiogram Qt Prolonged |
50.0% |
| Thrombocytopenia |
50.0% |
|
